InsiderSource
ELVN

Enliven Therapeutics, Inc.

SEC CIK 1672619
$46.13 +65.8% · 90 days
90-day buys
$0
0 open-market
90-day sells
$2.33M
11 open-market
Net insider flow
−$2.33M
Net selling
Filings shown
135
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at ELVN have sold a net $2.33M of stock (0 open-market buys vs 11 sells).

Largest recent trade: Lyssikatos Joseph P sold $1.46M of ELVN, trimming their stake 6%.

Most active filer: Lyssikatos Joseph P, with 56 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for ELVN, newest first
View on SEC EDGAR ↗
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Oct 8, 2024 ΔOwn −100%

Hohl Benjamin sold $281.1K of ELVN, trimming their stake 100%.

−$281.1K
10,218 sh @ $28
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Oct 3, 2024 ΔOwn −100%

Hohl Benjamin sold $14.3K of ELVN, trimming their stake 100%.

−$14.3K
521 sh @ $28
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Oct 1, 2024 ΔOwn −100%

Hohl Benjamin sold $50.7K of ELVN, trimming their stake 100%.

−$50.7K
2,000 sh @ $25
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Oct 1, 2024 ΔOwn −100%

Hohl Benjamin sold $103.2K of ELVN, trimming their stake 100%.

−$103.2K
4,250 sh @ $24
Advertisement
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Sep 3, 2024 ΔOwn −1.1%

Lyssikatos Joseph P sold $268.7K of ELVN, trimming their stake 1%.

−$268.7K
11,950 sh @ $22
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Aug 29, 2024 ΔOwn −100%

Hohl Benjamin sold $95.8K of ELVN, trimming their stake 100%.

−$95.8K
4,250 sh @ $23
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Aug 2, 2024 ΔOwn −100%

Hohl Benjamin sold $27.3K of ELVN, trimming their stake 100%.

−$27.3K
991 sh @ $28
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jul 31, 2024 ΔOwn −1.1%

Lyssikatos Joseph P sold $314.8K of ELVN, trimming their stake 1%.

−$314.8K
11,797 sh @ $27
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 31, 2024 ΔOwn −99%

Hohl Benjamin sold $138.4K of ELVN, trimming their stake 99%.

−$138.4K
5,189 sh @ $27
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 31, 2024 ΔOwn −100%

Hohl Benjamin sold $1.7K of ELVN, trimming their stake 100%.

−$1.7K
61 sh @ $27
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 16, 2024 ΔOwn −100%

Hohl Benjamin sold $75.2K of ELVN, trimming their stake 100%.

−$75.2K
3,000 sh @ $25
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jul 3, 2024 ΔOwn −1.1%

Lyssikatos Joseph P sold $274.7K of ELVN, trimming their stake 1%.

−$274.7K
12,000 sh @ $23
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 1, 2024 ΔOwn −30%

Hohl Benjamin sold $27.9K of ELVN, trimming their stake 30%.

−$27.9K
1,280 sh @ $22
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 1, 2024 ΔOwn −62%

Hohl Benjamin sold $41.3K of ELVN, trimming their stake 62%.

−$41.3K
1,830 sh @ $23
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Jul 1, 2024 ΔOwn −100%

Hohl Benjamin sold $26.7K of ELVN, trimming their stake 100%.

−$26.7K
1,140 sh @ $23
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed May 30, 2024 ΔOwn −45%

Hohl Benjamin sold $43.6K of ELVN, trimming their stake 45%.

−$43.6K
1,906 sh @ $23
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed May 30, 2024 ΔOwn −100%

Hohl Benjamin sold $54.7K of ELVN, trimming their stake 100%.

−$54.7K
2,334 sh @ $23
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed May 7, 2024 ΔOwn −100%

Hohl Benjamin sold $22.5K of ELVN, trimming their stake 100%.

−$22.5K
1,000 sh @ $23
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed May 1, 2024 ΔOwn −92%

Lyssikatos Joseph P sold $196.3K of ELVN, trimming their stake 92%.

−$196.3K
10,987 sh @ $18
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed May 1, 2024 ΔOwn −100%

Lyssikatos Joseph P sold $18.7K of ELVN, trimming their stake 100%.

−$18.7K
1,013 sh @ $18
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed May 1, 2024 ΔOwn −100%

Hohl Benjamin sold $55.2K of ELVN, trimming their stake 100%.

−$55.2K
3,250 sh @ $17
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Apr 15, 2024 ΔOwn −100%

Lyssikatos Joseph P sold $751.3K of ELVN, trimming their stake 100%.

−$751.3K
30,000 sh @ $25
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Apr 15, 2024 ΔOwn −27%

Hohl Benjamin sold $90.2K of ELVN, trimming their stake 27%.

−$90.2K
3,777 sh @ $24
ELVN
Enliven Therapeutics, Inc.
Sell Hohl Benjamin · CHIEF FINANCIAL OFFICER · Open-market sale · filed Apr 15, 2024 ΔOwn −100%

Hohl Benjamin sold $256K of ELVN, trimming their stake 100%.

−$256K
10,223 sh @ $25
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Apr 3, 2024 ΔOwn −20%

Lyssikatos Joseph P sold $41.7K of ELVN, trimming their stake 20%.

−$41.7K
2,352 sh @ $18
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Apr 3, 2024 ΔOwn −99%

Lyssikatos Joseph P sold $180.1K of ELVN, trimming their stake 99%.

−$180.1K
9,577 sh @ $19
Advertisement

About ELVN insider activity

This page tracks every recent Form 4 filed for Enliven Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is ELVN insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Enliven Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.